The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
Open accessAbstract
PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic efficacy of multiple mAbs targeting plasma membrane receptors involved in oncogenesis stems (at least in part) from their ability to bridge malignant cells and immune effector cells expressing Fc gamma receptors (Fc g Rs), culminating in antibody-dependent cellular cytotoxicity (ADCC) (Ferris et al., 2010).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Ferris et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,687
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112
Research works printed but not linked: 9
- Abes R, Blood
- Reilly RT, 2001, Cancer Res, 61, 880
- Sharafanski M, Head and Neck
- Valentini AM, 2008, Curr Opin Mol Ther, 10, 124
- Zhao WP, 2009, Oncol Rep, 21, 1405
- Whiteside TL, 1996, Anticancer Res, 16, 2357
- Ugurel S, 2002, Onkologie, 25, 129
- Li D, 2002, Cancer Res, 62, 4023
- 10.1158/1078-0432.CCR-05-2750 · DOI
Cited by
Sorted by citations
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,266
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 905
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B. A., Le, Q., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 794
Self-citationThe secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 708
Immunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 681
Self-citationTumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 565
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 450
Self-citationZaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 433
Carey, L., Berry, D. A., Cirrincione, C., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421
2011: the immune hallmarks of cancer
Cavallo, F., Giovanni, C. D., Nanni, P., Forni, G., & Lollini, P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 479
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417
Monoclonal Antibodies for Cancer Therapy
Scott, A. M., Allison, J. P., & Wolchok, J. D. (2012) · Springer eBooks · doi:10.1007/springerreference_303431 · Cited by 413
Srivastava, R. M., Lee, S. C., Filho, P. A. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López‐Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 321
Self-citationThe immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 287
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A. E., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 267
Self-citationEGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 233
Westphal, M., Heese, O., Steinbach, J. P., Schnell, O., Schackert, G., Mehdorn, H. M., Schulz, D., Simon, M., Schlegel, U. S., Senft, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.019 · Cited by 218
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204
HER2-targeted therapies in gastric cancer
Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188549 · Cited by 205
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 214
Petričević, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G. G., Bartsch, R., Jensen‐Jarolim, E., & Bergmann, M. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 202
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P. A., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 190
Imamura, M., Shook, D. R., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan‐Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 186
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M. S., Suni, M. A., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 179
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 186
Zhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 179
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177
Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis
Zhang, P., Zhai, Y., Cai, Y., Zhao, Y., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201904156 · Cited by 170
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167
Self-citationTheodoraki, M., Yerneni, S. S., Gooding, W. E., Ohr, J. P., Clump, D. A., Bauman, J. E., Ferris, R. L., & Whiteside, T. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593805 · Cited by 164
Self-citationPD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
Concha‐Benavente, F., Kansy, B., Moskovitz, J. M., Moy, J. D., Chandran, U. R., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 162
Self-citationArgiris, A. E., Harrington, K. J., Tahara, M., Schulten, J., Chomette, P., Castro, A. F., & Licitra, L. F. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00072 · Cited by 161
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Moskovitz, J. M., Moy, J. D., & Ferris, R. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0654-5 · Cited by 164
Self-citationTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedLee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
Self-citationTrastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Gall, V., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2774 · Cited by 156
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Wang, S., Zhang, Y., Wang, Y., Ye, P., Li, J., Li, H., Ding, Q., & Xia, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717892 · Cited by 147
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Monnier, P. P., Vigouroux, R. J., & Tassew, N. G. (2013) · Antibodies · doi:10.3390/antib2020193 · Cited by 142
Cohen, R. B. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.002 · Cited by 135
Padler‐Karavani, V., Hurtado‐Ziola, N., Pu, M., Yu, H., Huang, S., Muthana, S. M., Chokhawala, H. A., Cao, H., Secrest, P., Friedmann‐Morvinski, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4102 · Cited by 133
Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship
Monu, N. R., & Frey, A. B. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.673191 · Cited by 134
Bianchini, G., Pusztai, L., Pieńkowski, T., Im, Y., Bianchi, G., Tseng, L., Liu, M.-C., Lluch, A. M., Galeota, E., Magazzù, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv395 · Cited by 131
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 135
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 116
Self-citationFunctional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4
Campoli, M. R., Ferrone, S., & Wang, X. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00003-x · Cited by 118
Self-citationMittendorf, E. A., Ardavanis, A. S., Litton, J. K., Shumway, N. M., Hale, D. F., Murray, J. L., Perez, S. A., Ponniah, S., Baxevanis, C. N., Papamichail, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11751 · Cited by 112
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Disis, M. L., & Stanton, S. E. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e25 · Cited by 108
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
Moy, J. D., Moskovitz, J. M., & Ferris, R. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.035 · Cited by 102
Self-citationWu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 102
Clifton, G. T., Hale, D. F., Vreeland, T. J., Hickerson, A. T., Litton, J. K., Alatrash, G., Murthy, R. K., Qiao, N., Philips, A. V., Lukas, J. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2741 · Cited by 98
Lu, H., Yang, Y., Gad, E. A., Inatsuka, C., Wenner, C. A., Disis, M. L., & Standish, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1142 · Cited by 91
Alghamri, M. S., McClellan, B. L., Hartlage, C. S., Haase, S., Faisal, S. M., Thalla, R., Dabaja, A. A., Banerjee, K., Carney, S. V., Mujeeb, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680021 · Cited by 94
Expanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 88
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 84
Self-citationPillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 82
Ji, T., Lang, J., Ning, B., Qi, F., Wang, H., Zhang, Y., Zhao, R., Yang, X. P., Zhang, L., Li, W., et al. (2018) · Advanced Materials · doi:10.1002/adma.201804395 · Cited by 80
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 86
Lavrsen, K., Madsen, C. B., Rasch, M. G., Woetmann, A., Ødum, N., Mandel, U., Clausen, H., Pedersen, A. E., & Wandall, H. H. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9437-7 · Cited by 78
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77
Stephenson, R. M., Lim, C. M., Matthews, M., Dietsch, G. N., Hershberg, R. M., & Ferris, R. L. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1437-3 · Cited by 70
Self-citationNimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 74
Radiation therapy and immunotherapy: Implications for a combined cancer treatment
Lévy, A., Chargari, C., Cheminant, M., Simon‐Tillaux, N., Bourgier, C., & Deutsch, É. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.001 · Cited by 72
Tumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 71
Lee, S. C., Shimasaki, N., Lim, J. S. J., Wong, A. L., Yadav, K., Yong, W. P., Tan, L. K., Koh, L. P., Poon, M. L. M., Tan, S. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0768 · Cited by 68
Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M. L., Maloney, D. G., Press, O. W., Miller, T., & Rimsza, L. M. (2012) · Haematologica · doi:10.3324/haematol.2011.050419 · Cited by 70
Wang, D., Qian, G., Zhang, H., Magliocca, K. R., Nannapaneni, S., Amin, A. R. M. R., Rossi, M., Patel, M. R., El‐Deiry, M. W., Wadsworth, J. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0558 · Cited by 68
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Kroesen, M., Büll, C., Gielen, P. R., Brok, I. C., Armandari, I., Wassink, M., Looman, M. W. G., Boon, L., den Brok, M. H., Hoogerbrugge, P. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1164919 · Cited by 70
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 71
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64
Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification
Ma, Y., Ai, G., Zhang, C., Zhao, M., Dong, X., Han, Z., Wang, Z., Zhang, M., Liu, Y., Gao, W., et al. (2017) · Theranostics · doi:10.7150/thno.18401 · Cited by 62
Mazorra, Z., Lavastida, A., Concha‐Benavente, F., Valdés, A. F.-C., Srivastava, R. M., García-Bates, T. M., Esperanza, H., González, Z., González, A., Lugiollo, M., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00382 · Cited by 61
Self-citationLiu, X., Lu, Y., Huang, J., Xing, Y., Dai, H., Zhu, L., Li, S., Feng, J., Zhou, B., Li, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.015 · Cited by 59
The clinical implications of antitumor immunity in head and neck cancer
Allen, C. T., Judd, N. P., Bui, J. D., & Uppaluri, R. (2011) · The Laryngoscope · doi:10.1002/lary.21913 · Cited by 60
Gavriatopoulou, M., Kastritis, E., Ntanasis‐Stathopoulos, I., Fotiou, D., Ρούσσου, Μ., Migkou, M., Ziogas, D. C., Kanellias, N., Terpos, E., & Dimopoulos, M. A. (2017) · Blood · doi:10.1182/blood-2017-10-809293 · Cited by 59
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
Bauman, J. E., & Ferris, R. L. (2013) · Cancer · doi:10.1002/cncr.28380 · Cited by 58
Self-citationThe Immune Response to Tumors as a Tool toward Immunotherapy
Pandolfi, F., Cianci, R., Pagliari, D., Casciano, F., Bagalá, C., Astone, A., Landolfi, R., & Barone, C. A. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/894704 · Cited by 59
Carbohydrate-based cancer vaccines: target cancer with sugar bullets
Liu, C., & Ye, X. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9399-9 · Cited by 56
Siebert, N., Jensen, C., Troschke‐Meurer, S., Zumpe, M., Jüttner, M., Ehlert, K., Kietz, S., Müller, I., & Lode, H. N. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235108 · Cited by 59
Niwa, R., & Satoh, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24316 · Cited by 58
D’Aloia, M. M., Caratelli, S., Palumbo, C., Battella, S., Arriga, R., Lauro, D., Palmieri, G., Sconocchia, G., & Alimandi, M. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.10.014 · Cited by 54
Okuyama, K., Naruse, T., & Yanamoto, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02691-4 · Cited by 55
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Bezman, N., Jhatakia, A., Kearney, A. Y., Brender, T., Maurer, M. F., Henning, K. A., Jenkins, M. R., Rogers, A. J., Neeson, P. J., Korman, A. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017004382 · Cited by 54
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
Emens, L. A., Silverstein, S. C., Khleif, S. N., Marincola, F. M., & Galon, J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-70 · Cited by 54
Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review
Geynisman, D. M., Chien, C., Smieliauskas, F., Shen, C., & Shih, Y. T. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29407 · Cited by 54
Bauman, J. E., Cohen, E. E. W., Ferris, R. L., Adelstein, D. J., Brizel, D. M., Ridge, J. A., O’Sullivan, B., Burtness, B. A., Butterfield, L. H., Carson, W. E., et al. (2016) · Cancer · doi:10.1002/cncr.30449 · Cited by 51
Self-citationArgiris, A. E., Lee, S. C., Feinstein, T. M., Thomas, S. M., Branstetter, B. F., Seethala, R. R., Wang, L., Gooding, W. E., Grandis, J. R., & Ferris, R. L. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.034 · Cited by 50
Self-citationMeng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01455-z · Cited by 53
Control of Advanced Cancer: The Road to Chronicity
Lage, A., & Crombet, T. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8030683 · Cited by 46
Immune biomarkers of anti-EGFR monoclonal antibody therapy
Trivedi, S., Concha‐Benavente, F., Srivastava, R. M., Jie, H., Gibson, S. P., Schmitt, N. C., & Ferris, R. L. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu156 · Cited by 50
Self-citationAdvances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery
Bhadran, A., Polara, H., Babanyinah, G. K., Baburaj, S., & Stefan, M. C. (2025) · Cancers · doi:10.3390/cancers17142303 · Cited by 58
Lim, C. M., Stephenson, R. M., Salazar, A. Μ., & Ferris, R. L. (2013) · OncoImmunology · doi:10.4161/onci.24677 · Cited by 48
Self-citationCD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity
Pluhar, G. E., Pennell, C. A., & Olin, M. R. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2015013607 · Cited by 50
Neri, P. E., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 49
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032111 · Cited by 51
Metadata
- Authors
- Ferris, R. L., Jaffee, E. M., & Ferrone, S.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-01
- Volume
- 28
- Issue
- 28
- Pages
- 4390-4399
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2954137
- OpenAlex
- W2112887207
- Cited by
- 320
- References
- 122
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- American Society of Clinical Oncology
- National Cancer Institute (P50CA097190)
- National Institute of Dental and Craniofacial Research (R01DE019727)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
